HomeGNLX • NASDAQ
add
Genelux Corp
$3.05
Makalipas ang Oras ng Trabaho:(0.98%)+0.030
$3.08
Sarado: Hun 26, 7:30:53 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$2.94
Sakop ng araw
$2.87 - $3.05
Sakop ng taon
$1.60 - $5.89
Market cap
115.09M USD
Average na Volume
143.80K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 7.82M | -3.78% |
Net na kita | -7.49M | 4.56% |
Net profit margin | — | — |
Kita sa bawat share | -0.21 | 27.59% |
EBITDA | -7.76M | 3.41% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 35.10M | 78.85% |
Kabuuang asset | 38.98M | 57.99% |
Kabuuang sagutin | 9.14M | -4.72% |
Kabuuang equity | 29.85M | — |
Natitirang share | 37.30M | — |
Presyo para makapag-book | 3.68 | — |
Return on assets | -53.02% | — |
Return on capital | -65.38% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -7.49M | 4.56% |
Cash mula sa mga operasyon | -5.44M | -24.83% |
Cash mula sa pag-invest | 3.51M | 307.51% |
Cash mula sa financing | 9.57M | 1,290.55% |
Net change in cash | 7.64M | 242.64% |
Malayang cash flow | -2.66M | -103.16% |
Tungkol
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Itinatag
2001
Headquarters
Website
Mga Empleyado
24
